Plus Therapeutics Expands CNSide Assay Coverage to 126 Million with Elevance Health Deal
Event summary
- Plus Therapeutics' CNSide Diagnostics subsidiary secured a national coverage agreement with Elevance Health effective May 1, 2026.
- The deal covers approximately 45.4 million people, bringing total contracted coverage for the CNSide CSF TCE assay to 126 million.
- Over 11,000 tests have been performed since 2020 across more than 120 U.S. cancer institutions.
- The assay demonstrates 92% sensitivity and 95% specificity in detecting metastatic CNS cancer.
The big picture
This agreement significantly expands access to Plus Therapeutics' CNSide CSF assay, positioning it as a key player in metastatic CNS cancer diagnostics. The deal comes amid growing industry focus on precision oncology tools and value-based healthcare coverage models. With over 126 million people now covered, the company is well-positioned to capture market share in this niche but critical diagnostic segment.
What we're watching
- Market Penetration
- How Plus Therapeutics will leverage this expanded coverage to accelerate adoption in the metastatic CNS cancer diagnostics market.
- Revenue Growth
- Whether the increased patient access will translate into meaningful revenue growth for Plus Therapeutics' diagnostics segment.
- Competitive Positioning
- The pace at which competitors develop similar diagnostic technologies that could challenge CNSide's market share.
Related topics